Zenas Biopharma Inc (NASDAQ:ZBIO - Free Report) - Investment analysts at Wedbush issued their Q1 2025 EPS estimates for shares of Zenas Biopharma in a report issued on Thursday, March 20th. Wedbush analyst M. Fan anticipates that the company will post earnings of ($1.09) per share for the quarter. Wedbush has a "Outperform" rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas Biopharma's Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.33) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.43) EPS.
Separately, Guggenheim restated a "buy" rating and issued a $45.00 price target on shares of Zenas Biopharma in a research note on Wednesday, March 12th.
Check Out Our Latest Stock Report on Zenas Biopharma
Zenas Biopharma Stock Performance
Shares of NASDAQ:ZBIO traded down $0.03 during midday trading on Monday, reaching $8.03. The company had a trading volume of 174,508 shares, compared to its average volume of 187,124. Zenas Biopharma has a 1-year low of $5.83 and a 1-year high of $26.25. The company has a market cap of $335.65 million and a P/E ratio of -2.26.
Zenas Biopharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
Before you consider Zenas Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas Biopharma wasn't on the list.
While Zenas Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
